Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

Alona A. Merkulova, MA, Steven C. Mitchell, MA, Sergei Merkulov, PhD, Alisa S. Wolberg, PhD, Neerman-Arbez Marguerite, PhD, Alvin H. Schmaier, MD

Blood (2019) 134 (Supplement_1): 4934.

https://doi.org/10.1182/blood-2019-131319

Published: 2019

Journal Articles

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

Kosinsky Yuri, PhD, Lulu Chu, PhD, Millie Shah, PhD, Karthick Vishwanathan, PhD, Connie Larsson, PhD, Andrew Bloecher, PhD, Brandon Willis, PhD, Hannah Dry, BSc, Kirill Peskov, PhD, Joseph Ware, PhD, Andrew Mortlock, PhD, Gabriel Helmlinger, PhD

Blood (2019) 134 (Supplement_1): 5304.

https://doi.org/10.1182/blood-2019-130879

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Francis Ayuketang Ayuk, MD, Eva Maria Wagner, MD, Daniel Wolff, MD, Stephanie von Harsdorf, MD, Christian Koenecke, MD, Herbert G. Sayer, MD PhD, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 4523.

https://doi.org/10.1182/blood-2019-129801

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Blood (2019) 134 (Supplement_1): 810.

https://doi.org/10.1182/blood-2019-126192

Published: 2019

Journal Articles

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Guldane Cengiz Seval, Isinsu Kuzu, Seher Yuksel, Gulsah Kaygusuz, Klara Dalva, MD, Muhit Ozcan, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3197.

https://doi.org/10.1182/blood-2019-127541

Published: 2019

Journal Articles

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Blood (2018) 132 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2018-99-112944

Published: 2018

Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2018-99-115721

Published: 2018

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Katharina Kleinschmidt, MD PhD, Juergen Foell, MD, Johannes Schulte, Beatrix Pfirstinger, MD, Anja Troeger, MD, Charalampos Aslanidis, PhD, Daniel Wolff, MD, Matthias Edinger, MD PhD, Ernst Holler, MD, Wolfgang Herr, MD, Angelika Eggert, MD PhD, Selim Corbacioglu, MD

Blood (2018) 132 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2018-99-115988

Published: 2018

Journal Articles

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Neha Mehta-Shah, Nancy L. Bartlett

Blood (2018) 131 (15): 1698–1703.

https://doi.org/10.1182/blood-2017-09-772681

Published: 2018

Journal Articles

Everolimus Shows Synergistic Anti-Myeloma Effects with Bortezomib Via the AKT/mTOR Pathway

Hui Liu, Yun Liu, PhD, Rong Fu, PhD, Zonghong Shao, MD

Blood (2017) 130 (Supplement 1): 5396.

https://doi.org/10.1182/blood.V130.Suppl_1.5396.5396

Published: 2017

Journal Articles

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

Justin Keen, PhD, Dave Miller, PhD, Simon Tulloch, BA MA BM BCh

Blood (2017) 130 (Supplement 1): 2215.

https://doi.org/10.1182/blood.V130.Suppl_1.2215.2215

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 3910.

https://doi.org/10.1182/blood.V130.Suppl_1.3910.3910

Published: 2017

Journal Articles

Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study

Selim Corbacioglu, MD PhD, Juergen Foell, MD, Daniel Wolff, MD, Ernst Holler, MD, Beatrix Pfirstinger, MD, Klaus Thorsten Rehe, MD, Petra Hoffmann, PhD, Matthias Edinger, MD, Anja Troeger, MD, Svatava Srutkova, MD

Blood (2017) 130 (Supplement 1): 4594.

https://doi.org/10.1182/blood.V130.Suppl_1.4594.4594

Published: 2017

Journal Articles

Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas

Blood (2017) 130 (Supplement 1): 4056.

https://doi.org/10.1182/blood.V130.Suppl_1.4056.4056

Published: 2017

NARROW

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

Quantitative Investigation of Pharmacologically Modulated Signaling and Efficacy in ABC DLBCL Using a Systems Pharmacology Model

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Assessment of Calcineurin Inhibitor-Associated Neurotoxicity in Patients with Sickle Cell Disease Receiving a Matched Sibling Donor or T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Everolimus Shows Synergistic Anti-Myeloma Effects with Bortezomib Via the AKT/mTOR Pathway

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Digital Drug Screening and Computational Modeling Identifies Treatment Opportunities Despite Lack of Directly Actionable Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study

Simultaneous Global Phase I Studies of a Differentiated BTK Inhibitor, Dtrmwxhs-12, in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only